JAK1 and STING-associated vasculopathy with onset in infancy: Janus kinases (JAKs) have been targeted therapeutically in SAVI (10, 14, 34), and IFN receptors have preferential requirements for specific JAK proteins, including JAK1, JAK2, and TYK2 (35).